Tolerance Bio closes a $17.2 million round with the participation of Columbus and Criteria

by Columbus Venture Partners

Tolerance Bio is developing an allogeneic, or “off the shelf,” thymus induced pluripotent stem cell (iPSC)-based cell therapy platform as well as pharmacological thymus therapies to address immune...

Read more
Subscribe to Directory
Write an Article

Highlight

Axon moves into Cloud Technology

by Axon Partners Group

cloud technology axon

Xcalibur Smart Mapping strengthens its g...

by MCH Private Equity

​Xcalibur Smart Mapping, recognised as the global leader in airborne...

Photos Stream